All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.


The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Symposium | Practical management of adverse events with immunotherapies

Apr 9, 2024
Learning objective: After reading this article, learners will be able to employ patient-specific considerations in the development of personalized treatment plans.

Bookmark this article

During the Multiple Myeloma Hub virtual symposium held on March 11, 2024, “Current and future perspectives for bispecific antibodies in multiple myeloma: Learnings from 2023,” Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, US, delivered a presentation on the practical management of adverse events with immunotherapies in multiple myeloma.

Sergio Giralt provided an overview of the safety of bispecific antibodies in multiple myeloma, highlighting the common long-term effects associated with B-cell maturation antigen and G-protein coupled receptor family C group 5 member D targets (Figures 1 and 2). Then, Giralt shared recommendations for the management of late and delayed toxicities, including prophylactic and monitoring strategies.

Figure 1. Rationale for GPRC5D as a therapeutic target in MM* 

BMSC, Bone marrow stromal cells; DARA, daratumumab; GPRC5D, G protein-coupled receptor class C group 5 member D; HD, human donor; HLA, human leukocyte antigen; MM, multiple myeloma; PD, programmed death; POM, pomalidomide.
*Adapted from Smith, et al.1


Figure 2. Long-term effects of bispecific antibodies* 

BCMA, B-cell maturation antigen; CHIP, clonal hematopoiesis of indeterminate potential; CMV, cytomegalovirus; GPRC5D; G protein-coupled receptor class C group 5; HHV6, human herpesvirus 6; MDS, myelodysplastic syndrome; PCP, Pneumocystis pneumonia.
*Provided by Sergio Giralt.

This independent medical activity was funded by Janssen and Bristol Myers Squibb. All content was developed independently by the faculty. The funders were allowed no influence on the content of this activity.

  1. Smith E, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Science Translational Medicine. 2019;11(485):eaau7746. DOI: 1126/scitranslmed.aau7746.
  2. Moreau P, Garfall A, van de Donk N, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine. 2022;387(6):495-505. DOI: 1056/NEJMoa2203478.
  3. Link H, Kerkmann M, Holtmann L, et al. Immunoglobulin substitution in patients with secondary antibody deficiency in chronic lymphocytic leukemia and multiple myeloma: a representative analysis of guideline adherence and infections. Supportive Care in Cancer. 2022;30(6):5187-5200. DOI: 1007/s00520-022-06920-y.


Subscribe to get the best content related to multiple myeloma delivered to your inbox